Nanobodies News and Research

RSS

Driving up immunity at tumor site may help enhance immunotherapy treatments

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

14 Dec 2021

SARS-CoV-2 Omicron variant may bind with ACE2 receptor more efficiently

A new study discusses the effect of the Omicron variant’s mutations on its binding efficiency to the ACE2 receptor.

9 Dec 2021

Broad neutralization capability of potent nanobody against SARS-CoV-2 variants

A new study has described the molecular basis of the neutralization potency and breadth of nanobodies.

16 Nov 2021

New type of COVID vaccine potentially easier to produce and does not need refrigeration

Currently available COVID vaccines require cold storage and sophisticated manufacturing capacity, which makes it difficult to produce and distribute them widely, especially in less developed countries.

6 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Researchers have recently identified two nanobodies that show specific binding against a SARS-CoV-2 replication protein.

1 Nov 2021

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

In this study, a team of researchers from Japanese institutions provide a panel of broadly neutralizing nanobodies that detect four VOCs.

28 Oct 2021

A high-throughput pipeline for identifying nanobodies that target and neutralize SARS-CoV-2

Researchers in the United States have developed a cost-effective, high-throughput pipeline for identifying effective nanobodies that target and neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

26 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

Unique tiny Ilamas antibodies could be used for treatment of COVID-19

A unique type of tiny antibody produced by llamas could provide a new frontline treatment against Covid-19 that can be taken by patients as a simple nasal spray.

22 Sep 2021

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Researchers from the Broad Institute of MIT and Harvard have created a cell-free nanobody engineering platform that can produce antibodies effectively and quickly.

21 Sep 2021

The role of nanobodies in capturing and containing SARS-CoV-2

Scientists have repurposed the Nb Ty1 for the detection and neutralization of SARS-CoV-2.

8 Sep 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

Making the nanobody big again for Cryo-EM

Researchers describe the method that allows high-resolution structure determination of small proteins by single-particle cryo-EM using a Legobody.

17 Aug 2021

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

Multivalent nanobodies show improved neutralization activity against SARS-CoV-2

A state-of-the-art engineering approach toward improving the neutralizing activity of a cross-reactive nanobody, previously generated against the original SARS virus, showed it can be an attractive and viable option against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is published in the journal Advanced Therapeutics.

5 Aug 2021

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Mini-antibodies efficiently block SARS-CoV-2 virus

Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants.

28 Jul 2021

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

A new study has been published on the bioRxiv* preprint server, which has identified and characterized two RBD-targeting neutralizing nanobodies, namely, DL4 and DL28.

23 Jul 2021